A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).